A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
A new study shows that the Bubonic Plague has had a long-term impact on immune gene expression.
B cells are the immune cells responsible for creating antibodies, and most B cells produce antibodies in response to a pathogen or a vaccine, providing immunity.
Scientists examining the remains of 36 bubonic plague victims from a 16th century mass grave in Germany have found the first evidence that evolutionary adaptive processes, driven by the disease, may have conferred immunity on later generations of people from the region.
The Wistar Institute has developed a synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV).
Synthetic biologists have cracked open a cellular membrane, identifying a new method to boost the production yields of protein-based vaccines by five times.
In celebration of National DNA Day, AZoLifeSciences interviews renowned DNA expert Professor George Church about his life-long career in DNA research.
Research teams investigated the antibodies generated in people with symptomatic or asymptomatic SARS-CoV-2 infection.
Analytik reports how its Microfluidizer® processors are enabling researchers develop a range of therapeutic formulations including vaccine adjuvants, liposomes and lipid nanoparticles.
Large-scale supercomputer simulations at the atomic level show that the dominant G form variant of the COVID-19-causing virus is more infectious partly because of its greater ability to readily bind to its target host receptor in the body, compared to other variants.
The human genome contains the instructions to make tens of thousands of proteins. Each protein folds into a precise shape--and biologists are taught that defined shape dictates the protein's destined function. Tens of thousands of singular shapes drive the tens of thousands of needed functions.
Although it is known that mutations in the SARS-CoV-2 genome occurred and spread, the effect of those mutations is not yet clear.
A pre-clinical study for melanoma and neuroblastoma shows that a customized tumor cell vaccine technique that targets Myc oncogenes coupled with checkpoint therapy produces an active immune response that bypasses antigen selection and immune privilege.
Immunotherapy, which recruits the body's own immune system to attack cancer, has given many cancer patients a new avenue to treat the disease.
Researchers from Duke-NUS Medical School, the National Centre for Infectious Diseases (NCID), and the Agency for Science, Technology and Research (A*STAR) Infectious Diseases Labs have discovered that antibodies against SARS-CoV-2 decline at different speeds, and these antibodies last for only a few days in some people but remain for many years in other individuals.
Cancers that are resistant to radiotherapy could be rendered susceptible through treatment with immunotherapy, a new study suggests.
New research at Washington University School of Medicine in St. Louis indicates that three new, fast-spreading variants of the virus that cause COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic.
Researchers at the Lady Davis Institute (LDI) at the Jewish General Hospital have discovered that increased levels of the protein OAS1 are associated with reduced mortality and less severe disease requiring ventilation among patients with COVID-19.
Zika outbreaks are still having lasting effects on children whose mothers were infected with the Zika virus during their pregnancy.
In the course of a new and groundbreaking study, led by Dr, Natalia Freund and the doctoral candidate Avia Waston at the Sackler Medical Faculty, the research group succeeded in isolating monoclonal antibodies, which hindered the growth of tuberculosis germs in laboratory mice.
While neutralizing antibodies form in less than two weeks of a COVID-19 infection, their intensity and durability can differ from one individual to another.